Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop via mTORC2. Vistusertib, a dual inh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Schmid, Peter, Zaiss, Matthias, Harper-Wynne, Catherine, Ferreira, Marta, Dubey, Sidharth, Chan, Stephen, Makris, Andreas, Nemsadze, Gia, Brunt, Adrian M., Kuemmel, Sherko, Ruiz, Isabel, Perelló, Antonia, Kendall, Anne, Brown, Janet, Kristeleit, Hartmut, Conibear, John, Saura, Cristina, Grenier, Julien, Máhr, Károly, Schenker, Michael, Sohn, Joohyuk, Lee, Keun Seok, Shepherd, Christopher J., Oelmann, Elisabeth, Sarker, Shah-Jalal, Prendergast, Aaron, Marosics, Patricia, Moosa, Atiyyah, Lawrence, Cheryl, Coetzee, Carike, Mousa, Kelly, Cortés, Javier
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865233/
https://ncbi.nlm.nih.gov/pubmed/31465093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.2526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados